Clinical Trial for a new medication in Crohn's Disease
Details of Research
Contact:
Shlomit Boguslavsky, Clinical Research Coordinator
416-586-4800 ext. 4989
Shlomit.Boguslavsky@sinaihealth.ca
Primary Investigator: Dr. Hillary Steinhart
Enrolment: Ongoing
Mount Sinai Hospital is participating in a research study to
understand the safety and effectiveness of a investigational medication
for treating Crohn’s Disease.
This medication is given subcutaneously (by injection).
We are looking for individuals:
This study will last up to 6 years. Your Crohn’s Disease will be assessed and, if eligible, participants will be randomized in a 2:3:3 ratio to receive either placebo ("dummy" drug) or high dose study medication or low dose study medication. If your Crohn’s Disease has not improved by week 10 of the study, you may be eligible for the open-label (no placebo) portion of the study. Reimbursement will be provided for study-related travel expenses.